Novo Nordisk files for EU approval of Ozempic in type II diabetes

26th April 2019 Uncategorised 0

Patients treated with oral semaglutide demonstrated greater HbA1c reductions and weight loss.

More: Novo Nordisk files for EU approval of Ozempic in type II diabetes
Source: News